Regarding residual tumor and surgical management, recent studies (13, 49) underline how the activity of PARP-inhibitors is similar in patients with and without residual disease after surgery, however patients with complete gross resection followed by PARP-inhibitors therapy show greatest improvement in PFS rates. This evidence concerns the gene PARP1 and neoplasm.